Post Profile






Successful trial shows tablet lowers risk of disease returning for kidney cancer patients

Potentially practice-changing results have come out of an international study on how clinicians can reduce the risk of disease returning for kidney cancer patients. A trial demonstrates that taking oral tablet Sunitinib for one year reduces the likelihood of cancer returning for kidney cancer patients following removal of the kidney.
read more

share

Related Posts


Latest RAD001 Study Results Show Further Increase In Time Without Tumor Growth In Patients With Advanced Kidney Cancer

Health : Medical News Today

New data continue to demonstrate the potential benefit of RAD001 (everolimus) for patients with advanced kidney cancer who have failed standard therapies. Updated study findings from the RECORD-1 (REnal Cell cancer treatment with Or...

Sunitinib Benefits Patients with Renal Cell Carcinoma

Health : Newswise Medical News

Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals.

Comparison of pazopanib and sunitinib shows pazopanib offers better quality-of-life in advanced kidney cancer

Health : Medical News Today

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Instit...

First Large Prospective Clinical Study In Patients With CKD To Show That LDL-Cholesterol Lowering Medicine Reduces Atherosclerotic Events

Health : Medical News Today

Results from a randomised study in over 9,200 chronic kidney disease patients over nearly 5 years, published today in the Lancet, are the first to demonstrate that LDL-cholesterol lowering medicine reduced major atherosclerotic even...

Successful trial shows tablet lowers risk of disease returning for kidney cancer patients

Health : EurekAlert: Health

(University of Surrey) An international multi-center clinical trial, led in the UK by the University of Surrey, St. Luke's Cancer Centre and Royal Surrey County Hospital NHS Foundation Trust, produces potentially practice-changing r...

Comments


Copyright © 2016 Regator, LLC